2017 International Congress

June 4-8, 2017. Vancouver, BC.

View by Title View Sessions

View by Date

Tuesday, June 6, 2017

1:45pm-3:15pm: The Long-Term Safety of Deutetrabenazine for Chorea in Huntington Disease

S. Frank, C. Vaughan, D. Stamler, D. Oakes, M. Davis, S. Eberly, E. Kayson, J. Whaley, J. Goldstein, C. Testa (Boston, MA, USA)

Huntington's Disease · Exhibit Hall C

1:45pm-3:15pm: The nature of postural tremor in Parkinson’s disease

M. Dirkx, H. Zach, M. Hallet, R. Helmich (Nijmegen, Netherlands)

Parkinson's Disease: Pathophysiology · Exhibit Hall C

1:45pm-3:15pm: The neural correlates of apathy in premanifest and manifest Huntington’s disease: A cross-sectional multimodal imaging study

S. Martinez-Horta, J. Perez-Perez, F. Sampedro, M. Carceller, A. Horta-Barba, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

Huntington's Disease · Exhibit Hall C

1:45pm-3:15pm: The novel Parkinson´s disease locus RIT2 and alpha-synuclein function in intersecting pathways

M. Volta, J. Obergasteiger, C. Überbacher, C. Ascione, C. Corti, A. Hicks, P. Pramstaller (Bolzano, Italy)

Parkinson's Disease: Pathophysiology · Exhibit Hall C

1:45pm-3:15pm: The Personal Kinetigraph Fluctuator Score Identifies Motor Fluctuations in Parkinson’s disease

E. Tan, M. Tagliati, E. Hogg, M. Horne (Los Angeles, CA, USA)

Technology · Exhibit Hall C

1:45pm-3:15pm: The predominant parkinsonian phenotype in beta propeller associated neurodegeneration (BPAN)

H. Morales, B. Sanchez-Hernandez, R. Leal-Ortega, M. Rodriguez-Violante, M. Kurian, V. Fung (Westmead, NSW, Australia)

Genetics (Non-PD) · Exhibit Hall C

1:45pm-3:15pm: The Role of Clinical Outcome Assessment (COA) Data in the Drug Approval Process of Medicines for the Treatment of Restless Legs Syndrome (RLS): A Review of the Labels of Medicines Approved by the FDA and the EMA

M.-P. Emery, C. Anfray, L.-L. Perrier, C. Acquadro (Lyon, France)

Restless Legs Syndrome and Other Sleep Disorders · Exhibit Hall C

1:45pm-3:15pm: The therapeutic effects of cortical electrical stimulation in an animal model of Parkinson’s disease

T.-H. Hsieh, W.-S. Chang Chien, C.-W. Peng, Y.-Z. Hunag, J.-J. Chen (Taoyuan, Taiwan)

Therapy in Movement Disorders · Exhibit Hall C

1:45pm-3:15pm: The tricyclic antidepressant medication nortriptyline inhibits alpha-synuclein accumulation, aggregation and toxicity in multiple in vitro and in vivo models.

T. Collier, L. Lapidus, C. Sortwell, C. Justman, P. Lansbury, K. Paumier (Grand Rapids, MI, USA)

Parkinson's Disease: Pathophysiology · Exhibit Hall C

1:45pm-3:15pm: The value of the Tau/α-synuclein ratio and TNF-α in cerebrospinal fluid, and of plasma IL-6, in the diagnosis and prognosis of Parkinson’s disease

M. Delgado-Alvarado, B. Gago, A. Gorostidi, H. Jimenez-Urbieta, R. Dacosta-Aguayo, I. Navalpotro-Gómez, J. Ruiz-Martínez, A. Bergareche, J. Martí-Massó, P. Martínez-Lage, A. Izagirre, M. Rodríguez-Oroz (San Sebastián, Spain)

Parkinson's Disease: Pathophysiology · Exhibit Hall C